A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: fluconazole
- drug: PF-06647020 Q3W
- drug: PF-06647020 Q2W
- drug: PF-06647020 combined with Avelumab
Eligibility
Q2W Inclusion Criteria:
- Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
lines, or recurrent advanced NSCLC having received 3 or fewer prior lines
- Performance Status of 0, 1, or 2
- Adequate bone marrow, kidney, and liver function
Q2W Exclusion Criteria:
- OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
mullerian tumors, unresolved bowel obstruction
- Brain metastases requiring steroids
- Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
study treatment start
- Active and clinically significant bacterial, fungal, or viral infection
Q3W Inclusion Criteria:
- Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
or for whom no standard therapy is available
- Performance Status of 0 or 1
- Adequate bone marrow, kidney, and liver function
- Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
non small cell lung cancer patients
Q3W Exclusion Criteria:
- OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
unresolved bowel obstruction
- Brain metastases requiring steroids
- Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
study treatment start
- Active and clinically significant bacterial, fungal, or viral infection
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
ccto
ccto-office@stanford.edu
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.
